Income Taxes (Details Narrative) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 22, 2017 |
Dec. 31, 2018 |
Dec. 31, 2017 |
|
| Income tax examination description | The "Tax Cuts and Jobs Act" (Public Law No. 115-97), enacted on December 22, 2017, is a comprehensive revision to federal tax law which makes broad and complex changes to the U.S. tax code, including, but not limited to, reducing the U.S. federal corporate tax rate to 21% from 35% | ||
| Income tax expense | |||
| Operating loss carry forward expiration, description | begin to expire in 2035 | begin to expire in 2035 | |
| Estimated research and development tax credit carryforwards | $ 91,535 | $ 194,345 | |
| Tax Cuts and Jobs Act [Member] | |||
| Revised U.S. corporate federal income tax rate | 21.00% | 35.00% | |
| Income tax expense | $ 1,600,000 | ||
| Federal [Member] | |||
| Net opertaing loss carryforwards | $ 22,900,000 | ||
| State [Member] | |||
| Net opertaing loss carryforwards | $ 13,800,000 | ||
| X | ||||||||||
- Definition Operating loss carry forward expiration, description. No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|